Module

Targeting Integrase: Mechanisms of Action and Mechanisms of Resistance to Integrase Inhibitors

Source: The Role of Integrase Inhibitors in HIV Management

Targeting Integrase: Mechanisms of Action and Mechanisms of Resistance to Integrase Inhibitors

Faculty:

Martin Markowitz, MD

CME CREDIT INFORMATION

Release Date: 05/15/08

Expiration Date: 05/14/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the role of the integrase enzyme in the HIV replication cycle
Discuss the mechanism of action of the current integrase strand transfer inhibitors raltegravir and elvitegravir
Summarize the findings regarding the development of resistance in clinical trials of elvitegravir and raltegravir
Discuss issues relating to cross-resistance between the integrase inhibitors elvitegravir and raltegravir

Topics covered include:

Introduction
Role of HIV Integrase in Viral Replication
Integrase Inhibitor Mechanisms of Action
Mechanisms of Resistance to Integrase Inhibitors
Treatment-Emergent Resistance to Raltegravir
Resistance to Elvitegravir
Cross-Resistance to Integrase Inhibitors
Conclusions
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.